دورية أكاديمية
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
| العنوان: | Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment |
|---|---|
| المؤلفون: | Palanques-Pastor, Tomás, Megías-Vericat, Juan Eduardo, Bosó Ribelles, Virginia, Gómez Seguí, Inés, Poveda Andrés, José Luis |
| المصدر: | Acta Haematologica ; volume 145, issue 1, page 72-77 ; ISSN 0001-5792 1421-9662 |
| بيانات النشر: | S. Karger AG |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Hematology, General Medicine |
| الوصف: | Acquired thrombocytopenic thrombotic purpura (aTTP) is an autoantibody-mediated disease against the enzyme A Disintegrin and Metalloprotease domain with ThromboSpondin-1 type motif 13, which until now has been treated with plasma exchange (PEX) and corticosteroids. A 29-year-old female patient, who presented with aTTP in the context of pregnancy, has developed multiple relapses after treatment with PEX, corticosteroids, and rituximab. Recently, caplacizumab, a nanobody against von Willebrand factor, has been approved for the treatment of aTTP. In our patient, caplacizumab achieved better disease control, with a lower platelet count restoration time, days of PEX and hospitalization duration, as compared to standard therapy, reproducing the results of clinical trials. Caplacizumab represents a significant advance in the treatment of aTTP, especially in cases of recurrent relapses. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1159/000517813 |
| الإتاحة: | https://doi.org/10.1159/000517813Test https://www.karger.com/Article/Pdf/517813Test |
| حقوق: | https://www.karger.com/Services/SiteLicensesTest ; https://www.karger.com/Services/SiteLicensesTest |
| رقم الانضمام: | edsbas.1F74C894 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1159/000517813 |
|---|